Search Within

Michael David Offin

Formats
  1. Meeting Abstract (88)
  2. Journal Article (75)
  3. Editorial (4)
  4. Review (4)
  5. Conference Paper (1)
  6. Correspondence (1)
Groups
  1. Department of Medicine (173)
  2. Solid Tumor Oncology Division (173)
  3. Thoracic Oncology (173)
  4. Weinberg Fellows (173)
  5. Department of Pathology and Laboratory Medicine (113)
  6. GSK Faculty (111)

More Groups

People
  1. Charles Rudin (69)
  2. Marc Ladanyi (59)
  3. Mark Kris (57)
  4. Alexander Drilon (53)
  5. Bob Li (53)
  6. Marjorie Zauderer (45)

More People

Years
  1. 2025 (6)
  2. 2024 (23)
  3. 2023 (16)
  4. 2022 (25)
  5. 2021 (34)
  6. 2020 (20)

More Years

Publications
  1. Journal of Thoracic Oncology (32)
  2. Journal of Clinical Oncology (29)
  3. Clinical Cancer Research (12)
  4. International Journal of Radiation Oncology, Biology, Physics (12)
  5. Annals of Oncology (8)
  6. Modern Pathology (8)

More Publications

Publishers
  1. Elsevier Inc. (52)
  2. American Society of Clinical Oncology (37)
  3. American Association for Cancer Research (21)
  4. Oxford University Press (14)
  5. Nature Publishing Group (9)
  6. Nature Research (8)

More Publishers

Results (173)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Molecular and imaging predictors of response to ado-trastuzumab emtansine in patients with HER2 mutant lung cancers: An exploratory phase 2 trial
    Meeting Abstract

    Li, B.; Offin, M.; Hembrough, T.; Cecchi, F.; Shen, R.; Olah, Z.; Panora, E.; Myers, M.; Brzostowski, E.; Buonocore, D.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Detecting HER2 alterations by next generation sequencing (NGS) in patients with advanced NSCLC from the United States and China
    Meeting Abstract

    Xu, C.; Zhang, Y.; Liu, D.; Shen, R.; Razavi, P.; Liu, S.; Sun, H.; Offin, M.; Drilon, A.; Rudin, C.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • MET exon 14-altered lung cancers: Central nervous system (CNS) metastases and patterns of CNS progression on MET inhibition
    Meeting Abstract

    Offin, M.; Dienstag, J.; Wilkins, O.; Sabari, J.; Ni, A.; Feldman, D.; Van Voorthuysen, M.; Suzawa, K.; Yu, H.; Riely, G.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Utility of cfDNA testing for acquired resistance: The Memorial Sloan Kettering experience with plasma EGFR T790M clinical testing
    Meeting Abstract

    Offin, M.; Myers, M.; Josyula, S.; Shen, R.; Borsu, L.; Tsui, D.; Riely, G.; Rudin, C.; Yu, H.; Li, B.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Clinical and molecular characteristics of EGFR mutant lung cancers with concurrent TP53 and RB1 mutations
    Meeting Abstract

    Offin, M.; Tenet, M.; Shen, R.; Rekhtman, N.; Rizvi, H.; Hellmann, M.; Arcila, M.; Ladanyi, M.; Rudin, C.; Kris, M.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Entrectinib: An orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
    Journal Article

    Liu, D.; Offin, M.; Harnicar, S.; Li, B. T.; Drilon, A.
    Therapeutics and Clinical Risk Management (2018)

    Fulltext@MSK | Save
  • Liquid biopsy guided precision therapy for lung cancers
    Journal Article

    Xu, C.; Offin, M.; Paik, P. K.; Li, B. T.
    Journal of Thoracic Disease (2018)

    Fulltext@MSK | Save
  • Tumor-agnostic drug development
    Journal Article

    Offin, M.; Liu, D.; Drilon, A.
    American Society of Clinical Oncology Educational Book (2018)

    Fulltext@MSK | Save
  • PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers
    Journal Article

    Sabari, J. K.; Leonardi, G. C.; Shu, C. A.; Umeton, R.; Montecalvo, J.; Ni, A.; Chen, R.; Dienstag, J.; Mrad, C.; Bergagnini, I.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: Results from a phase II basket trial
    Journal Article

    Li, B. T.; Shen, R. L.; Buonocore, D.; Olah, Z. T.; Ni, A.; Ginsberg, M. S.; Ulaner, G. A.; Offin, M.; Feldman, D.; Hembrough, T.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save